The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification

Background: The European Society of Medical Oncology Scale for Clinical Actionability of Molecular Targets (ESCAT) classification system provides a standardized framework for categorizing genomic alterations (GAs) of patients with recurrent, metastatic, or rare cancer. This study aimed to present ou...

Full description

Saved in:

Bibliographic Details
Main Authors:	K. Rahmani Narj Abadi, C. Dupain, I. Guillou, R. Sanchez, K. Nedara, G. Marret, S. Hescot, M-P. Sablin, Z. Castel-Ajgal, C. Neuzillet, E. Borcoman, D. Bello Roufai, M. Rodrigues, A. Asnacios Lecerf, C. Callens, O. Trabelsi-Grati, S. Melaabi, K. Driouch, S. Antonio, E. Lemaitre, M. Nijnikoff, A. Vincent Salomon, Y. Allory, J. Cyrta, H. Ghazelian, E. Girard, N. Servant, D. Stoppa-Lyonnet, J. Wong, A. Hamza, J. Masliah-Planchon, M. Kamal, I. Bièche, C. Le Tourneau
Format:	Article
Language:	English
Published:	Elsevier 2024-12-01
Series:	ESMO Real World Data and Digital Oncology
Subjects:	precision medicine molecular tumor board actionable genomic alteration ESCAT classification clinical trial
Online Access:	http://www.sciencedirect.com/science/article/pii/S2949820124000705
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification

Similar Items